Children wearing spectacle lenses: mobility during everyday activities

Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses

This test checks whether myopia-control spectacle lenses change how children aged 6–12 move and perform everyday mobility tasks compared with regular single-vision glasses.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 6 Years to 12 Years
• Sex: All
• Sponsor: SightGlass Vision, Inc. (Industry-sponsored)
• Locations: 1 site (Glendale, Arizona)
• Trial ID: NCT07229352 on ClinicalTrials.gov

What this trial studies

Children aged 6 to 12 who meet vision and health criteria will be fitted with either standard single-vision spectacle lenses (control) or a novel myopia-control spectacle lens design (test) and will perform a series of everyday mobility tasks during in-person visits. The study compares mobility performance between the two lens types using structured tasks and observational measures to capture real-world functional effects. Participants must be able to achieve 20/20 with correction, have no active ocular disease, and have not been undergoing other myopia-control treatments. Visits are conducted at a single clinical site where trained staff record performance and adherence to lens wear instructions.

Who should consider this trial

Good fit: Ideal candidates are children aged 6–12 who can achieve 20/20 vision with correction, have no active ocular disease, have not recently used myopia-control treatments, and whose parent or guardian can provide informed consent and attend study visits.

Not a fit: Children outside the 6–12 age range, those who cannot achieve 20/20 vision with correction, have active ocular or excluded systemic disease, or are currently on myopia-control treatments are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, the results could show that myopia-control spectacle lenses do not impair—and may be safely used without reducing—children's mobility in daily activities, supporting clinician and parent confidence in prescribing them.

How similar studies have performed: Previous trials of myopia-control lens designs have shown success in slowing refractive progression, but relatively few studies have specifically examined effects on children's mobility and everyday functional tasks, so this focus is partly novel.

Eligibility criteria

Inclusion Criteria:

A participant is eligible for inclusion in the study if they meet the following criteria:

* Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent/assent.
* Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
* Have undergone a self-reported oculo-visual examination within the past two years.
* Have no active ocular disease.
* Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
* Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.
* The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.

Exclusion Criteria:

A participant will be excluded from the study if they meet any of the following conditions:

* Have any systemic disease that affects ocular health.
* Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
* Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
* Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
* Have known developmental delays.
* Have participated in another clinical study in the last 7 days

Where this trial is running

Glendale, Arizona

• Midwestern University Arizona College of Optometry — Glendale, Arizona, United States (Recruiting)

Study contacts

• Study coordinator: Jennifer Hill

Conditions Myopia; Myopia Progression; Juvenile Myopia